Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor

พุธ 13 พฤษภาคม 2552 เวลา 09:58 น.

NERVIANO--13 May--PRNewswire-AsiaNet/InfoQuest

The FDA has approved an Investigational New Drug (IND) application by Nerviano Medical Sciences to begin a phase I clinical study with its selective PLK-1 small molecule inhibitor for the treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation of cancer cells. This new compound is orally bioavailable, highly efficient and well tolerated in preclinical models of cancer after repeated dosing. This unique inhibitor adds another promising candidate to the pipeline of innovative cell cycle targets with different mechanisms of action in clinical development which have been discovered and developed by NMS. These include inhibitors of

CDK, Aurora and CDC-7. An IND for an inhibitor of CDC-7 was approved by the FDA in January this year and the first patients were treated with the compound in April. NMS CDK and Aurora inhibitors are in phase I and II

clinical development, respectively, and are starting to show promising activity in specific patient populations.

The clinical development path foresees application of the NMS PLK-1 inhibitor in solid and hematological indications. "I am pleased to see the second IND approval this year and I highly appreciate the consistant delivery of high quality clinical candidates by the Nerviano site" comments Dr. Francesco Colotta, VP R&D at NMS.

Nerviano Medical Sciences (NMS)

Nerviano Medical Sciences is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe. Research activities in

Nerviano generate on average two clinical candidate molecules per year. NMS takes advantage of strategic alliances with biotechnology as well as pharmaceutical companies to secure its long term business sustainability. The Company has already finalized partnerships with major companies such as Pfizer Inc., Bristol-Myers Squibb Co., Genentech Inc. as well as with several biotech companies and academic institutions.

For information:

Nerviano Medical Sciences

Maria D'Acquino,

tel +39-0331-581013,

mob. +39-335-1863051,

maria.dacquino@nervianoms.com

SOURCE: Nerviano Medical Sciences

--Distributed by AsiaNet ( www.asianetnews.net )--

ข่าวNerviano Medical Sciences+innovativeวันนี้

Kia EV3 Study Car made with BASF's sustainable and high-performance material solutions

Kia EV3 Study Car is the 3rd concept car collaboration between Hyundai-Kia and BASF Hyundai-Kia and BASF have once again co-created for its 3rd concept car the Kia EV3 Study Car, an experimental model developed together with Hyundai-Kia's Materials Research & Engineering Center of the Advanced Vehicle Platform division. Made with BASF's innovative and sustainable performance materials, the Kia EV3 Study Car is designed to enhance both the vehicle's performance, design, functionalities and

08 เมษายน 2568 17:29 น.

แนร์วิอาโน เมดิคัล ไซน์ส ได้รับอนุญาตจากองค์การอาหารและยาสหรัฐให้ทำการทดลองยาต้าน Polo Like Kinase (PLK) ในมนุษย์ในขั้นแรกได้

องค์การอาหารและยาสหรัฐ (FDA) ได้อนญาตให้ แนร์วิอาโน เมดิคัล ไซน์ส (Nerviano Medical Sciences หรือ NMS) เริ่มการทดลองทางคลินิกขั้นแรกสำหรับยาต้าน PLK-1 ซึ่งเป็นยาต้านโม... พ.ค. 52